Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to discuss the future ...

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

NYSE:PFE Earnings and Revenue History November 11th 2025 How Do Unusual Items Influence Profit? To properly understand Pfizer ...

Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. As a result, Vertex should be worth more than Pfizer by 2030.

In September, the telecommunications giant announced it was boosting its dividend by 1.25 cents a share to $0.69 per share, its 19th consecutive annual dividend increase. At the current share price, ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the ...

The U.S. drugmaker submitted its sweetened bid, which matches Novo’s offer from Tuesday, valuing Metsera at $86.20 a share, ...

Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Wall Street analysts forecast that Pfizer (PFE) will report quarterly earnings of $0.66 per share in its upcoming release, pointing to a year-over-year decline of 37.7%. It is anticipated that ...

Jon Smith explains why investors can look across the pond for stocks with attractive dividend forecasts and shares a specific ...